000 | 01945 a2200613 4500 | ||
---|---|---|---|
005 | 20250517042157.0 | ||
264 | 0 | _c20160823 | |
008 | 201608s 0 0 eng d | ||
022 | _a1476-5365 | ||
024 | 7 |
_a10.1038/bmt.2015.165 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aMichelis, F V | |
245 | 0 | 0 |
_aPatient age, remission status and HCT-CI in a combined score are prognostic for patients with AML undergoing allogeneic hematopoietic cell transplantation in CR1 and CR2. _h[electronic resource] |
260 |
_bBone marrow transplantation _cNov 2015 |
||
300 |
_a1405-10 p. _bdigital |
||
500 | _aPublication Type: Journal Article | ||
650 | 0 | 4 | _aAdolescent |
650 | 0 | 4 | _aAdult |
650 | 0 | 4 | _aAge Factors |
650 | 0 | 4 | _aAged |
650 | 0 | 4 | _aAllografts |
650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
650 | 0 | 4 | _aCombined Modality Therapy |
650 | 0 | 4 | _aComorbidity |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aHematopoietic Stem Cell Transplantation |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aKaplan-Meier Estimate |
650 | 0 | 4 |
_aLeukemia, Myeloid, Acute _xmortality |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 |
_aNeoplasms, Second Primary _xmortality |
650 | 0 | 4 | _aPrognosis |
650 | 0 | 4 | _aRecurrence |
650 | 0 | 4 | _aRemission Induction |
650 | 0 | 4 | _aRetrospective Studies |
650 | 0 | 4 | _aSalvage Therapy |
650 | 0 | 4 | _aSeverity of Illness Index |
650 | 0 | 4 | _aTransplantation Conditioning |
650 | 0 | 4 | _aYoung Adult |
700 | 1 | _aMessner, H A | |
700 | 1 | _aAtenafu, E G | |
700 | 1 | _aMcGillis, L | |
700 | 1 | _aLambie, A | |
700 | 1 | _aUhm, J | |
700 | 1 | _aAlam, N | |
700 | 1 | _aSeftel, M D | |
700 | 1 | _aGupta, V | |
700 | 1 | _aKuruvilla, J | |
700 | 1 | _aLipton, J H | |
700 | 1 | _aKim, D D | |
773 | 0 |
_tBone marrow transplantation _gvol. 50 _gno. 11 _gp. 1405-10 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1038/bmt.2015.165 _zAvailable from publisher's website |
999 |
_c25067902 _d25067902 |